Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA ...

Eli Lilly’s LLY recent announcement to acquire Verve Therapeutics, Inc VERV, a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, has put the spotlight on ...

On the final trading day of 2025, Cathie Wood put an eye-brow raising $1.33 million to work in Intellia Therapeutics ( NTLA ) ...

Cathie Wood is making a massive bet on gene editing, pouring $5.4 billion into companies like Beam Therapeutics while selling ...

The gene therapy market is surging toward $36.55 billion by 2032, powered by rising demand for curative treatments that target genetic diseases at their source([1]) . The FDA approved three ...

Cathie Wood’s Ark Invest increased exposure to gene-editing names and autonomous mobility companies while further cutting ...

Cathie Wood has seldom shied away from letting everyone know where she believes the next wave of market-changing businesses ...

Krystal Biotech, Inc. (NASDAQ:KRYS) is one of the best gene-editing stocks to buy according to hedge funds. On November 5, Evercore ISI’s Gavin Clark-Gartner affirmed a Buy rating on Krystal Biotech, ...

On Tuesday, Eli Lilly And Co (NYSE:LLY) agreed to acquire Verve Therapeutics, Inc. (NASDAQ:VERV), a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease. Lilly ...

Shares of gene editing companies were largely steady in the premarket on Friday after the FDA’s Center for Biologics Research and Evaluation (CBER) faced another abrupt leadership transition following ...

Now, it’s worth noting Stock Advisor’s total average return is 991 % — a market-crushing outperformance compared to 196% for ...

In this article, we will take a look at the 9 Best Gene-Editing Stocks to Buy According to Hedge Funds. Genetic manipulation – or gene editing – is a concept that describes altering the genetic ...